Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 11,142.7% in August

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 616,887 shares, an increase of 11,142.7% from the August 15th total of 5,487 shares. Based on an average daily volume of 893,115 shares, the short-interest ratio is presently 0.7 days. Currently, 5.5% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on APRE shares. Wedbush dropped their price target on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.07.

Aprea Therapeutics Trading Down 0.3%

Shares of Aprea Therapeutics stock opened at $0.79 on Friday. The company has a market cap of $9.94 million, a PE ratio of -0.73 and a beta of 1.54. The company has a 50 day moving average of $0.72 and a 200-day moving average of $0.78. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.69.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 47.60%. Research analysts forecast that Aprea Therapeutics will post -0.34 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A number of institutional investors have recently modified their holdings of APRE. Jane Street Group LLC acquired a new position in Aprea Therapeutics during the fourth quarter worth about $40,000. DRW Securities LLC bought a new position in shares of Aprea Therapeutics in the fourth quarter worth about $103,000. Finally, AIGH Capital Management LLC boosted its stake in shares of Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after purchasing an additional 645,000 shares in the last quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.